Elaine Heron Purchases 2,400 Shares of Palvella Therapeutics (NASDAQ:PVLA) Stock

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Director Elaine Heron acquired 2,400 shares of the stock in a transaction dated Friday, February 27th. The stock was acquired at an average price of $125.00 per share, with a total value of $300,000.00. Following the completion of the acquisition, the director owned 47,812 shares in the company, valued at approximately $5,976,500. The trade was a 5.28% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Palvella Therapeutics Stock Performance

Shares of PVLA stock opened at $131.51 on Wednesday. Palvella Therapeutics, Inc. has a fifty-two week low of $18.23 and a fifty-two week high of $151.18. The stock has a 50 day moving average price of $95.63 and a two-hundred day moving average price of $81.70. The company has a market capitalization of $1.56 billion, a P/E ratio of -50.00 and a beta of -0.30.

Hedge Funds Weigh In On Palvella Therapeutics

Several large investors have recently made changes to their positions in PVLA. Archer Investment Corp acquired a new stake in Palvella Therapeutics in the third quarter valued at approximately $28,000. Group One Trading LLC raised its holdings in Palvella Therapeutics by 151.5% in the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after acquiring an additional 200 shares during the last quarter. Russell Investments Group Ltd. purchased a new position in Palvella Therapeutics in the 3rd quarter worth approximately $36,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Palvella Therapeutics during the 2nd quarter worth approximately $37,000. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after purchasing an additional 3,242 shares during the last quarter. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Cantor Fitzgerald boosted their target price on Palvella Therapeutics from $120.00 to $200.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. BTIG Research upped their price target on Palvella Therapeutics from $192.00 to $215.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. Chardan Capital raised their target price on shares of Palvella Therapeutics from $174.00 to $210.00 and gave the company a “buy” rating in a report on Tuesday, February 24th. Mizuho increased their target price on shares of Palvella Therapeutics from $205.00 to $250.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th. Finally, TD Cowen reissued a “buy” rating on shares of Palvella Therapeutics in a research note on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $176.44.

Palvella Therapeutics News Roundup

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Directors bought stock at the offering price, signaling insider confidence — Director Elaine Heron purchased 2,400 shares at $125/share (and George M. Jenkins also increased his stake). Insider buys can be viewed as management backing the company after the offering. Article Title
• Positive Sentiment: Palvella closed an upsized public offering that raised $230M (1,840,000 shares at $125, including full exercise of the underwriters’ option). The cash should extend runway and fund clinical programs (QTORIN rapamycin and pitavastatin), which reduces near‑term financing risk. Article Title
• Positive Sentiment: Analyst coverage remains constructive with multiple buy/strong-buy ratings and elevated price targets (consensus materially above current levels), which can support sentiment and provide a valuation anchor for investors. Article Title
• Neutral Sentiment: Market commentary is reassessing Palvella’s valuation after strong recent gains and a high price-to-book multiple — this is analysis-focused and may increase scrutiny but isn’t new company-specific news. Article Title
• Negative Sentiment: Share issuance is dilutive: the 1.84M new shares at $125 increases float and can create short-term selling pressure as the market absorbs supply. Some outlets flagged that reliance on offering proceeds underscores clinical-stage risk (no FDA approvals yet). Article Title

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.